Phase 1 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People whose acute lymphoblastic leukaemia (ALL) has come back or has not responded to at least one previous treatment, and whose disease either got worse after the last treatment or never went into full remission with it
- People with a type of ALL linked to the Philadelphia Chromosome, if the disease progressed, stayed stable, or came back after at least one treatment that included a type of drug called a tyrosine kinase inhibitor (TKI)
- People whose leukaemia cells test positive for a marker called CD19 (confirmed by laboratory testing)
- Children and young people aged 1 to 18 years, of any sex
- People with a physical ability score (measured by the Lansky or Karnofsky scale) of 50 or above, meaning they are able to carry out some daily activities
- People whose liver, kidney, and lung function fall within acceptable ranges on blood and oxygen tests
- People who have waited the required amount of time since their last cancer treatment before the cell-collection procedure (leukapheresis) — the exact waiting period depends on the type of treatment last received (confirm with trial site)
- People whose steroid medication use has been stable or reducing for at least one week before joining, and is at or below a low daily dose (confirm with trial site)
- People (and/or their caregivers) who are willing and able to give written informed consent
Who may not be able to join:
- People who have active graft-versus-host disease (GVHD) that required immune-suppressing medication within the four weeks before enrolment
- People with a history of another active cancer, other than certain minor skin cancers or very early-stage cancers in place (such as early cervical, bladder, or breast)
- People with ongoing or uncontrolled serious illness, such as an active infection, significant heart problems, serious lung conditions, active GVHD, or mental health or social circumstances that would make it difficult to follow the study requirements
- People who are pregnant or breastfeeding, because the CAR-T cell therapy used in this trial may carry risks to an unborn baby or nursing infant
- People of childbearing or child-fathering potential who are not willing to use birth control from the time of enrolment through to four months after receiving the CAR-T cell treatment
- People who show signs of a bone marrow condition called myelodysplasia, based on prior bone marrow testing
- People with an active HIV, hepatitis B, or hepatitis C infection (certain test results related to past hepatitis exposure may also affect eligibility — confirm with trial site)
- People who have had a severe allergic reaction (anaphylaxis) to albumin in the past
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kanhatai Chiengthong, MD, King Chulalongkorn Memorial Hospital
Phone: +66817515363
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence and Severity of Adverse Events of CD19-IL7Ra CAR T-cells infusion in B-cell acute lymphoblastic leukemia patients.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.